Johnson & Johnson has announced positive topline results from a Phase III study evaluating Caplyta (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder. The study met its primary endpoint, with Caplyta demonstrating a statistically significant and rapid… Read More
AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF) has been approved in the European Union (EU) as a maintenance treatment for asthma. It is approved in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose… Read More
AstronauTx has received funding from The Michael J Fox Foundation for Parkinson’s Research (MJFF), while Parkinson’s UK is funding an additional complementary research effort in collaboration with University College London (UCL). The MJFF-funded project, titled ‘Ligand-Gated Ion Channel Modulation as a Disease-Modifying Treatment for Prodromal Synucleinopathies’, will… Read More
The Edinburgh Genome Foundry (EGF), one of the world’s leading bio-foundries, is collaborating with The Advanced Research and Invention Agency (ARIA) to accelerate biological research and unlock new discoveries that benefit everyone. The three-year programme will provide ARIA with access to and expansion of EGF’s automated laboratory… Read More
Palomar Labs (formerly Negev Labs), a venture studio that builds companies around neuropsychiatric drug development programmes with prior human validation, has announced the spinout of Ariadne Bio, its first portfolio company. Ariadne Bio launches with lead programme AB-300, a clinical-stage-ready, non-hallucinogenic serotonin 2A receptor agonist in development… Read More
Novo Nordisk and Orbis Medicines have announced a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. Under the terms of the agreement, Orbis Medicines is eligible to receive up to $1.4 billion in upfront and potential development and commercial milestone… Read More
Scottish deep-tech company Chemify has received £22 million ($29.7 million) in grants from Scottish Enterprise and the UK Government. The funding will support a significant expansion of Chemify’s capacity to digitise molecular discovery, synthesis and scale-up through a new Chemifarm. The grant package includes £16… Read More
Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases. The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed. VHB937… Read More
Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases. Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for… Read More
A new resource is now available to download for free. Efficient assay preparation and reliable affinity measurements are critical to successful screening campaigns. This technical note explores how Dianthus uHTS can be integrated with Echo Acoustic Liquid Handling to support automated, miniaturised affinity screening workflows. Download the App Note to… Read More
A new company founded by Deep Science Ventures veterans has closed a £1.5 million (~$2m) pre-seed round and secured £700,000 (~$950K) Innovate UK funding. Big Picture Bio has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how… Read More
Circio Holding has successfully completed a private placement raising gross proceeds to the company of approx. NOK 200 ($21) million, through the allocation of 16,865,000 new shares. The Offer Price corresponds to a 9% discount to the volume weighted average share price (VWAP) quoted for trade in… Read More
US researchers have filed a class action lawsuit challenging the National Institutes of Health’s (NIH) policy of blocking grants to censor views it disagrees with, on everything from DEI to gender identity to climate change. The plaintiffs are represented by the American Civil Liberties Union, the ACLU… Read More
Arrowhead Pharmaceuticals has announced interim topline data from a Phase I/IIa clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both… Read More
The Chordoma Foundation’s TBXT Challenge was won by X-Chem, securing the company $100,000 in milestone awards. X-Chem was the first of 26 participating teams to discover a compound that binds Brachyury (TBXT) below the 1 micromolar threshold. TBXT is a key vulnerability in chordoma, a… Read More
Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab). The fully-human EGFR-MET bispecific antibody was assessed with carboplatin-pemetrexed chemotherapy, versus chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth… Read More
